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Abstract
A facile Pd-catalyzed C(sp2)–N coupling to provide a range of 2- or 4-[(subst.)phenyl]amino-13α-estrone derivatives has been
achieved under microwave irradiation. The reactions were mediated with the use of Pd(OAc)2 as a catalyst and KOt-Bu as a base in
the presence of X-Phos as a ligand. The desired products have been obtained in good to excellent yields. The nature and the posi-
tion of the aniline substituent at the aromatic ring influenced the outcome of the couplings. 2-Amino-13α-estrone was also synthe-
sized in a two-step protocol including an amination of 2-bromo-13α-estrone 3-benzyl ether with benzophenone imine and subse-
quent hydrogenolysis.
Introduction
Aminoestrones are of particular interest thanks to their diverse
biological applications [1-4]. There exist several aminated
steroids in the literature, but the efficient generation of a
C(sp2)–N bond on the aromatic ring A of estrone derivatives
still remains a challenge. Aminoestrones substituted at C-2 or
C-4 are mainly produced by the reduction or hydrogenation of
the corresponding nitro derivatives [5]. Classical nitration
methods have, however, many drawbacks concerning elevated
reaction temperatures, long reaction times, and poor yields. The
introduction of amino or substituted amino groups onto ring A
of estrone is fascinating from both organic chemical and biolog-
ical points of view. Certain ring A-aminated estrone derivatives
are described as inhibitors of estrogen biosynthesis. They are
often synthesized via a three-step method including nitration,
reduction, and functionalization of the amino group [1,2]. This
three-step protocol may be simplified to involve only
one or two steps by the application of a Pd-catalyzed Buch-
wald–Hartwig amination. In recent years, extensive efforts have
been made on the Pd(0)-catalyzed amination of aryl halides or
triflates in order to achieve the efficient synthesis of substituted
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anilines [6-9]. Buchwald et al. stated that the Pd source is deter-
mining in the amination step [9]. They also found that X-Phos is
an outstanding ligand with increased activity and stability com-
pared to those based on BINAP [10].
There are a number of literature methods with respect to micro-
wave-assisted Buchwald–Hartwig couplings [11-13]. Many
publications have reported remarkable advantages of micro-
wave-assisted syntheses, including shorter reaction times,
higher yields and chemoselectivity [14-16].
Concerning the aromatic ring A of estrone, the Pd-catalyzed
Buchwald–Hartwig amination was carried out exclusively at
position C-3, starting from the 3-triflate derivative [17,18]. The
C(sp2)–N cross-coupling of the triflate was achieved with
benzophenone imine or benzylamine. The removal of the
protecting groups resulted in 3-aminoestrone in high yields.
Schön et al. developed two convenient protocols for the prepa-
ration of 3-aminoestrone using Pd(OAc)2 and Pd2(dba)3 as cata-
lysts, X-Phos as a ligand, Cs2CO3 as a base in toluene or DMF
solvent under thermal heating or microwave irradiation [18].
We recently described halogenations [19] and Sonogashira
couplings on ring A of 13α-estrone and its 3-methyl ether [20].
The 13-epimer of natural estrone is a non-natural C-18 steroid
containing cis junction of rings C and D [21,22]. This core-
modified compound differs from its natural 13β counterpart not
only in the configuration of C-13, but also its more flexible con-
formation. Poirier et al. investigated the in vitro and in vivo
estrogenic activity of 3,17-estradiol derivatives of 13α-estrone
[23]. The 13-epimers were shown to exhibit no significant
binding affinity for estrogen receptor alpha and display no
uterotropic activity. Nevertheless, certain 13α-estrone deriva-
tives possess important biological activities including antitu-
moral effect [24-27]. Thus 13α-estrone is a suitable compound
for the development of biologically active steroids lacking
estrogenicity. Literature reveals that besides the inversion of
C-13, the introduction of an amino group onto C-2 or C-4 of
estrone also leads to significant decreases in its binding affinity
for nuclear estrogen receptors (ERα and ERβ) [28]. Certain de-
rivatives of 2- or 4-aminoestrone or their 3-methyl ether pos-
sess diverse biological activities, including enzyme inhibitory or
antiproliferative properties [1-3,29,30]. The 17β-HSD1 enzyme
is responsible for the reduction of estrone into 17β-estradiol,
which may enhance the proliferation of tumor cells [31]. Effec-
tive inhibition of 17β-HSD1 may result in an antitumor effect in
hormone-dependent cancers [32]. It is known that several 2- or
4-substituted estrone derivatives possess substantial 17β-HSD1
inhibitory action [19,20,33]. The presence of a large lipophilic
group on C-2 of estrone was found to be advantageous concern-
ing the 17β-HSD1 inhibitory activity [33]. Chin et al. reported
that 2-bromoacetamidoestrone 3-methyl ether inhibits the
17β-HSD1 enzyme in an irreversible manner [1]. Nevertheless,
we proved that certain 4-halogenated 13α-estrone 3-methyl
ethers are also effective inhibitors [19]. Recently, we carried out
the Pd-catalyzed C–C coupling of 2- and 4-iodo-13α-estrones as
well as their 3-methyl ethers with p-substituted phenyl-
acetylenes as terminal alkyne partners under microwave irradia-
tion [20]. The regioisomerism markedly influenced the reaction
conditions. 2-Iodo isomers were transformed using Pd(PPh3)4
catalyst and CuI as a cocatalyst. Reactions of the 4-iodo coun-
terparts could be achieved by changing the catalyst to
Pd(PPh3)2Cl2 and using higher temperature. Additionally, the 2-
or 4-phenylethynyl derivatives were partially or completely
saturated in order to get stereochemically different compounds
for structure–activity determinations. The saturated derivatives
contain a phenyl moiety at C-2 attached through an ethenediyl
or ethanediyl linker. Of the synthesized 2- and 4-regioisomers,
solely the 2-counterparts bearing a 3-OH group exhibited a sub-
stantial inhibitory effect against the 17β-HSD1 enzyme. Sur-
prisingly, the enzyme inhibitory action did not depend on the
hybrid state of carbon attached to C-2. From the pharmacologi-
cal point of view it would be interesting to synthesize and in-
vestigate such 13α-estrone derivatives, bearing a lipophilic phe-
nyl group attached to C-2 through an amino linker.
In continuation of our studies with respect to cross-coupling
reactions on ring A of 13α-estrone, here we disclose the devel-
opment of a Pd-catalyzed C(sp2)–N coupling methodology for
the transformation of 2-bromo- and 4-bromo-13α-estrone
3-methyl (1 or 3) as well as 3-benzyl ethers (2 or 4) with aniline
or substituted anilines as reagents. To the best of our know-
ledge, there are no literature reports concerning the Pd-cata-
lyzed 2- or 4-amination of the estrane core.
Results and Discussion
Based on recent literature results [18,20], we started to opti-
mize the reaction conditions for the transformation of 2-bromo-
13α-estrone 3-methyl ether (1) with aniline (Table 1). Since the
Pd source has been shown to be crucial in the amination step,
two Pd catalysts were investigated. Namely, Pd(OAc)2 and
Pd2(dba)3 were used in the presence of X-Phos or BINAP as
ligands. The literature data influenced the selection of the base.
The arylation of anilines, escpecially of unsubstituted ones with
o-bromoanisoles requires stronger bases such as NaOt-Bu or
KOt-Bu [34-38]. This is due to the deactivated, electron-rich
nature of anisoles induced by the electron-donating methoxy
group. Taking into account the above-mentioned observations
[18,34-38], couplings were performed in the presence of DBU,
NaOt-Bu, KOt-Bu or Cs2CO3 as the base. Toluene was chosen
as a solvent, and the reactions were carried out under micro-
wave irradiation or thermal heating. The solvent was selected
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Table 1: Effect of the reaction conditions on the Pd-catalyzed amination of 2-bromo-13α-estrone 3-methyl ether (1) with aniline in toluenea.
entry Pd source (mol %) ligand (mol %) base temp (°C) 5b (%) 5c (%)
1 Pd(OAc)2 (10) X-Phos, 10 DBU 150 41 44
2 Pd(OAc)2 (10) X-Phos, 10 KOt-Bu 150 77 80
3 Pd(OAc)2 (10) X-Phos, 10 KOt-Bu 100 83 80
4 Pd(OAc)2 (10) X-Phos, 10 NaOt-Bu 150 74 80
5 Pd(OAc)2 (10) X-Phos, 10 NaOt-Bu 100 78 81
6 Pd(OAc)2 (10) X-Phos, 10 Cs2CO3 150 0 0
7 Pd(OAc)2 (10) BINAP, 10 DBU 150 21 22
8 Pd(OAc)2 (10) BINAP, 10 KOt-Bu 150 35 37
9 Pd(OAc)2 (10) BINAP, 10 NaOt-Bu 150 28 26
10 Pd(OAc)2 (10) BINAP, 10 Cs2CO3 150 0 0
11 Pd2(dba)3 (5) X-Phos, 10 DBU 150 0 0
12 Pd2(dba)3 (5) X-Phos, 10 KOt-Bu 150 12 12
13 Pd2(dba)3 (5) X-Phos, 10 NaOt-Bu 150 10 11
14 Pd2(dba)3 (5) X-Phos, 10 Cs2CO3 150 0 0
15 Pd2(dba)3 (5) BINAP, 10 DBU 150 0 0
16 Pd2(dba)3 (5) BINAP, 10 KOt-Bu 150 8 10
17 Pd2(dba)3 (5) BINAP, 10 NaOt-Bu 150 7 10
18 Pd2(dba)3 (5) BINAP, 10 Cs2CO3 150 0 0
aReagents and conditions: 2-bromo-13α-estrone 3-methyl ether (1, 1 equiv), aniline (1.2 equiv). bFlash chromatography yield obtained under conven-
tional heating (24 h, reflux temperature). cFlash chromatography yield obtained under microwave irradiation (10 min).
on the basis of literature data reported for other Pd-catalyzed
reactions of estrone derivatives [18,20]. The pre-stirring of the
reaction mixture without adding the aryl halide 1 was carried
out at 60 °C for 5 min in a water bath, then aryl halide 1 was
added and the mixture was irradiated in a microwave reactor at
150 °C for 10 min. The outcome of the couplings greatly
depended on the nature of the Pd source, the ligand and the
base.
As summarized in Table 1, reactions with pre-catalyst
Pd(OAc)2 gave the desired aminoestrone 5 in low to high yields
(Table 1, entries 1, 2, 4, 7–9) except when using Cs2CO3 as the
base (Table 1, entries 6 and 10). In the latter cases only dehalo-
genation of the starting aryl halide was observed in around
20–60% yield. The use of KOt-Bu (Table 1, entries 2 and 8) or
NaOt-Bu (Table 1, entries 4 and 9) as bases seemed to be more
advantageous over the use of DBU (Table 1, entries 1 and 7).
Concerning the ligand applied, it can be stated that reactions
with X-Phos (Table 1, entries 1–6) resulted in higher yields in
comparison to couplings with BINAP (Table 1, entries 7–9). As
seen in Table 1, our expectations failed concerning couplings
induced by Pd2(dba)3 as the catalyst (Table 1, entries 11–18).
None of the Pd2(dba)3–base–ligand combinations gave com-
pound 5 successfully. Only reactions in the presence of KOt-Bu
(Table 1, entries 12, 16) or NaOt-Bu (Table 1, entries 13, 17)
led to the formation of compound 5, but in very low yields. The
starting aryl halide 1 was mostly recovered, and neither dehalo-
genation nor C(sp2)–N coupling occurred.
After finding the best set of reaction conditions (Table 1, entries
2 and 4), the temperature was lowered to 100 °C (Table 1,
entries 3 and 5) in order to suppress the dehalogenation side
reaction. The efficiency of the couplings was found to be simi-
lar to that observed at higher temperature with improved yields.
Nevertheless, reaction with KOt-Bu (Table 1, entry 3) proved to
be slightly more efficient.
In order to compare the efficiency and reaction time of thermal
heating with microwave-irradiation conditions, all reactions of 1
with aniline were performed under both conditions (Table 1,
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Scheme 1: Pd-catalyzed aminations at C-2 or C-4 in the 13α-estrone series. Reactions were performed on a 0.25 mmol scale with 1.2 equiv of
amine, 10 mol % Pd(OAc)2, 10 mol % X-Phos, at 100 °C, 10 min under microwave irradiation. Flash chromatography yields are reported.
entries 1–18). As seen in Table 1, similar yields might be
achieved, but reaction times differ considerably (10 min vs
24 h).
On the basis of the optimization procedure discussed above, we
selected microwave-assisted conditions at lower temperature
(Table 1, entry 3) for further transformations.
With the best reaction conditions in hand, the couplings at C-2
of starting compound 1 were extended to monosubstituted
anilines bearing electronically different substituents at o, m or p
positions (Scheme 1).
As indicated in Scheme 1, all couplings proceeded with high
yields. The best yields were achieved with nitroanilines, irre-
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Scheme 2: Two-step synthesis of 2-amino-13α-estra-1,3,5(10)-trien-17-one (13).
spective of the position of the nitro group. Reaction of methyl-
anilines led to slightly lower yields, indicating that the presence
of the electron-donating methyl group is less advantageous over
the electron-withdrawing nitro function. The coupling at C-4 of
compound 1 with aniline under the same conditions yielded
aminated derivative 10 in high yield.
With an attempt to investigate the influence of the size of the
3-ether group, 2- or 4-bromo isomers of 3-benzyl ethers 2 or 4
were also submitted to C(sp2)–N couplings with aniline using
the procedure elaborated above. Irrespective of the more bulky
nature of the benzyl ether group compared to its methyl coun-
terpart, compounds 2 and 4 were successfully aminated
affording derivatives 6 and 11 without the need of changing the
reaction conditions established for couplings at C-2.
In continuation of our earlier work concerning the synthesis of
2-substituted 3-hydroxy-13α-estrone derivatives as potential en-
zyme inhibitors [20], here we were interested in the synthesis of
2-amino-13α-estrone (13). The efficient C(sp2)–N coupling
method elaborated above proved to be suitable for the reaction
of 2-bromo-3-benzyl ether 2 and benzophenone imine as an
amine precursor (Scheme 2). The deprotection was achieved by
hydrogenolysis using a Pd/C catalyst. The resulting newly-syn-
thesized 2-amino-13α-estrone (13) itself may possess promis-
ing pharmacological properties or may serve as a key intermedi-
ate in the synthesis of biologically active 2-(subst.)amino-13α-
estrones.
The structures of the newly synthesized phenylamino deriva-
tives 5–13 were established through 1H, 13C, HSQC and/or
HMBC measurements.
Conclusion
In conclusion, we have developed a convenient microwave-
assisted one-step protocol for the facile and efficient prepara-
tion of 2- and 4-phenylaminoestrones 5–11. Our method affords
the desired products in short reaction times in good to excellent
yields. Thanks to the elaborated mild coupling procedure, the
synthesis of 2-amino-13α-estrone 13 could be achieved in only
two steps without the first, aromatic nitration step used exten-
sively earlier. The newly synthesized amino derivatives of 13α-
estrone 5–13 may possess important biological activities with-
out hormonal effect.
Supporting Information
Supporting Information File 1
Experimental procedures for compounds 5–13, their
1H, 13C NMR, MS, elemental analysis data and the copies
of their 1H and 13C NMR spectra.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-14-85-S1.pdf]
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